How This Evidence Evolved
IgA Nephropathy Treatment
From supportive care to targeted immunosuppression and novel endothelin-angiotensin blockade
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Current standard of care and ongoing research directions
12-month UPCR geometric mean reduction: sibeprenlimab 2/4/8 mg/kg 47.2%/58.8%/62.0% vs placebo 20.0%
Week 24 UPCR change: combined 75/150 mg atacicept −31% vs placebo −8%; reported 25% relative reduction
Month 9 UPCR: iptacopan 38.3% lower than placebo (95% CI 26.0–48.6); efficacy analysis first 250 randomized
Landmark Trials in This Story
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
3-y immunosuppression/supportive care: remission 17%/5% (P=.01); eGFR fall ≥15 mL/min/1.73m²: 26%/28% (P=.75)
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial
Composite kidney endpoint over mean 4.2 years: methylprednisolone 28.8% vs placebo 43.1% (HR 0.53, 95% CI 0.39–0.72)
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
404 treated; primary: proteinuria change at 36 weeks. Secondary chronic eGFR slope: sparsentan −2.7 vs irbesartan −3.8 mL/min/1.73m²/year.
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
12-month UPCR geometric mean reduction: sibeprenlimab 2/4/8 mg/kg 47.2%/58.8%/62.0% vs placebo 20.0%
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Week 24 UPCR change: combined 75/150 mg atacicept −31% vs placebo −8%; reported 25% relative reduction
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Month 9 UPCR: iptacopan 38.3% lower than placebo (95% CI 26.0–48.6); efficacy analysis first 250 randomized
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.